Equities analysts expect Axsome Therapeutics Inc (NASDAQ:AXSM) to post earnings per share (EPS) of ($0.33) for the current quarter, Zacks reports. Zero analysts have made estimates for Axsome Therapeutics’ earnings. Axsome Therapeutics posted earnings per share of ($0.28) in the same quarter last year, which would indicate a negative year over year growth rate of 17.9%. The firm is scheduled to announce its next earnings report on Wednesday, March 6th.
On average, analysts expect that Axsome Therapeutics will report full-year earnings of ($1.13) per share for the current year, with EPS estimates ranging from ($1.18) to ($1.09). For the next fiscal year, analysts forecast that the company will report earnings of ($1.09) per share, with EPS estimates ranging from ($1.19) to ($0.94). Zacks’ earnings per share averages are an average based on a survey of research analysts that follow Axsome Therapeutics.
Axsome Therapeutics (NASDAQ:AXSM) last issued its quarterly earnings data on Friday, November 9th. The company reported ($0.31) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.33) by $0.02.
Several hedge funds and other institutional investors have recently made changes to their positions in the business. Worth Venture Partners LLC bought a new position in shares of Axsome Therapeutics during the third quarter valued at approximately $138,000. Sio Capital Management LLC increased its stake in shares of Axsome Therapeutics by 115.5% during the third quarter. Sio Capital Management LLC now owns 416,458 shares of the company’s stock valued at $1,437,000 after purchasing an additional 223,168 shares in the last quarter. Finally, Alethea Capital Management LLC increased its stake in shares of Axsome Therapeutics by 102.1% during the third quarter. Alethea Capital Management LLC now owns 547,443 shares of the company’s stock valued at $1,889,000 after purchasing an additional 276,620 shares in the last quarter. 10.71% of the stock is owned by institutional investors and hedge funds.
AXSM traded up $0.02 on Tuesday, hitting $3.26. The company had a trading volume of 46,053 shares, compared to its average volume of 194,470. The company has a debt-to-equity ratio of 6.00, a current ratio of 1.46 and a quick ratio of 1.46. Axsome Therapeutics has a 52-week low of $2.05 and a 52-week high of $5.95. The firm has a market capitalization of $97.19 million, a PE ratio of -2.63 and a beta of -0.51.
About Axsome Therapeutics
Axsome Therapeutics, Inc, a clinical stage biopharmaceutical company, is developing novel therapies for central nervous system (CNS) disorders. Its product candidate portfolio includes AXS-05, AXS-09, AXS-02, AXS-07, and AXS-06. AXS-05 is in the Phase III clinical trial in treatment resistant depression and in agitation associated with Alzheimer's disease, as well as in the Phase II clinical trial for smoking cessation.
Featured Story: What is a Call Option?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.